Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
Stoke Therapeutics, Inc is a biotechnology business based in the US. Stoke Therapeutics shares (STOK) are listed on the NASDAQ and all prices are listed in US Dollars. Stoke Therapeutics employs 56 staff and has a market cap (total outstanding shares value) of USD$1.7 billion.
|Latest market close||USD$45.02|
|52-week range||USD$15.82 - USD$50|
|50-day moving average||USD$41.1289|
|200-day moving average||USD$31.064|
|Wall St. target price||USD$48.13|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-11.439|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||-6.19%|
|1 month (2020-11-06)||12.92%|
|3 months (2020-09-04)||56.43%|
|6 months (2020-06-05)||82.64%|
|1 year (2019-12-05)||79.86%|
|2 years (2018-12-02)||N/A|
|3 years (2017-12-02)||N/A|
|5 years (2015-12-02)||N/A|
Valuing Stoke Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Stoke Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Stoke Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 22x. In other words, Stoke Therapeutics shares trade at around 22x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Gross profit TTM||USD$0|
|Return on assets TTM||-14.11%|
|Return on equity TTM||-22.45%|
|Market capitalisation||USD$1.7 billion|
TTM: trailing 12 months
There are currently 2.9 million Stoke Therapeutics shares held short by investors – that's known as Stoke Therapeutics's "short interest". This figure is 1% down from 2.9 million last month.
There are a few different ways that this level of interest in shorting Stoke Therapeutics shares can be evaluated.
Stoke Therapeutics's "short interest ratio" (SIR) is the quantity of Stoke Therapeutics shares currently shorted divided by the average quantity of Stoke Therapeutics shares traded daily (recently around 92480.220135966). Stoke Therapeutics's SIR currently stands at 30.89. In other words for every 100,000 Stoke Therapeutics shares traded daily on the market, roughly 30890 shares are currently held short.
However Stoke Therapeutics's short interest can also be evaluated against the total number of Stoke Therapeutics shares, or, against the total number of tradable Stoke Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Stoke Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Stoke Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.2252% of the tradable shares (for every 100,000 tradable Stoke Therapeutics shares, roughly 225 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Stoke Therapeutics.
Find out more about how you can short Stoke Therapeutics stock.
We're not expecting Stoke Therapeutics to pay a dividend over the next 12 months.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.
Steps to owning and managing HTZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing HELE, with 24-hour and historical pricing before you buy.
Steps to owning and managing HE, with 24-hour and historical pricing before you buy.
Steps to owning and managing GKOS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYEN, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXAS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EVFM, with 24-hour and historical pricing before you buy.
Steps to owning and managing MRAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQNR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SOLO, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.